Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - UPDATE ON PROGRESS FOR ADALIMUMAB INJECTION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

VOLUNTARY ANNOUNCEMENT

- UPDATE ON PROGRESS FOR ADALIMUMAB INJECTION

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技 股份有限公司) (the "Company") on a voluntary basis. Reference is also made to the overseas

regulatory announcement of the Company dated 8 November 2019.

The board of directors of the Company is pleased to announce that recently, the Company and its subsidiary, Suzhou Union Biopharm Biosciences Co., Ltd.* (蘇州眾合生物醫藥科技有限公

司), have received the Acceptance Notice for the new drug application in respect of adalimumab injection (product code: UBP1211) issued by the National Medical Products Administration. Information of the drug is summarized as follows:

Drug name:	Adalimumab injection
Acceptance No.:	CXSS1900041 Guo (CXSS1900041國)
Subject matter:	New drug application: Special access programme
Applicants:	Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公
	司) and Suzhou Union Biopharm Biosciences Co., Ltd.* (蘇州眾合生物醫藥
	科技有限公司)
Conclusion:	New drug application accepted

The Company will, according to the progress of the new drug application of this project, perform the information disclosure obligation in a timely manner. Investors are advised to pay continuous attention in this regard.

1

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company may not be able to ultimately develop and market UBP1211 successfully. Investors are reminded to exercise caution.

By order of the Board of

Shanghai Junshi Biosciences Co., Ltd.*

Mr. Xiong Jun

Chairman

Shanghai, the PRC, 8 November 2019

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Wu Hai and Dr. Yao Sheng as executive Directors; Mr. Tang Yi, Mr. Li Cong, Mr. Yi Qingqing and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Dr. He Jia, Mr. Chen Xinjun, Mr. Qian Zhi and Dr. Roy Steven Herbst as independent non-executive Directors.

• For identification purpose only

2